Halley E. Gilbert Appointed to Arcutis Board of Directors
April 27 2020 - 8:30AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Halley E. Gilbert has been appointed to the Arcutis Board of
Directors effective May 1, 2020.
“We are thrilled to welcome Halley to the
Arcutis Board,” said Frank Watanabe, Arcutis’ President and Chief
Executive Officer. “She is an exceptionally talented Board Director
and industry executive with over two decades of experience in
legal, corporate and business development, compliance and
government affairs. Her wealth of experience in building and
growing successful commercial-stage biotechnology companies will be
invaluable as we continue to advance Arcutis’ robust dermatology
pipeline.”
“I am delighted to join the Arcutis board at
this exciting time, following its successful recent IPO and with
its multiple Phase 2 and Phase 3 data readouts anticipated within
the next 18-24 months,” said Halley Gilbert. “I applaud the
company’s strategy to identify and develop treatments against
validated biological targets in dermatology to deliver
differentiated treatments that addresses the shortcomings of
existing therapies. I look forward to contributing my expertise,
specifically that within dermatology, to help them build a leading
dermatology company.”
Ms. Gilbert was most recently with Ironwood
Pharmaceuticals, where she had been Senior Vice President for
Corporate Development and Chief Administrative Officer, and
oversaw corporate and business development, legal, compliance
and government affairs. Previously, she had been Ironwood’s Senior
Vice President, Chief Legal Officer and Corporate Secretary. Prior
to joining Ironwood, Ms. Gilbert was Vice President, Deputy General
Counsel at Cubist Pharmaceuticals, Inc. and previously served as a
corporate counsel at Genzyme Corp., prior to its acquisition by
Sanofi. She began her career at Skadden, Arps, Slate, Meagher &
Flom LLP, where she specialized in mergers and acquisitions and
securities law.
Ms. Gilbert previously served on the board of
directors for Dermira, Inc. (acquired by Eli Lilly and Company), a
commercial-stage company focused on medical dermatology drugs, and
Achaogen, Inc., a commercial-stage biopharmaceutical company that
developed novel antibacterial therapies.
Ms. Gilbert holds a B.A. in Political Science
from Tufts University and J.D. from Northwestern University School
of Law.
About Arcutis - Bioscience,
applied to the skin.Arcutis is a late-stage biopharmaceutical
company focused on developing and commercializing treatments for
unmet needs in immune-mediated dermatological diseases and
conditions, or immuno-dermatology. Arcutis exploits recent
innovations in inflammation and immunology to develop potential
best-in-class therapies against validated biological targets,
leveraging our deep development, formulation and commercialization
expertise to bring to market novel dermatology treatments, while
maximizing our probability of technical success and financial
resources. Arcutis is currently developing three novel
compounds, including topical roflumilast cream (ARQ-151), topical
roflumilast foam (ARQ-154) and ARQ-252 for multiple indications,
including psoriasis, atopic dermatitis, seborrheic dermatitis and
hand eczema. For more information, please visit www.arcutis.com or
follow the Company on LinkedIn.
Forward Looking StatementsThis
press release contains forward-looking statements, including but
not limited to statements regarding Arcutis’ pipeline and
development programs; the potential for Arcutis’ development
compounds to be best-in-class; and the anticipated timing of data
readouts. Such forward-looking statements involve substantial risks
and uncertainties that could cause Arcutis’ clinical development
programs, future results, performance or achievements to differ
significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the drug development
process, including the clinical trial enrollment process,
regulatory approval processes, the potential timing of regulatory
filings, the challenges associated with manufacturing drug
products, Arcutis’ ability to successfully protect and defend its
intellectual property, and other matters that could affect the
sufficiency of existing cash to fund operations and the
availability or commercial potential of Arcutis product candidates.
Arcutis undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of the Company in general, see
Arcutis’ filings with the U.S. Securities and Exchange Commission,
including the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2019, and any subsequent current and
periodic reports.
Contact:Heather Rowe Armstrong Vice President,
Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024